TY - JOUR AU - Renu*, AU - B.Pushpalatha, AU - K.Bharathi, AU - Devendra Singh, PY - 2020/01/17 Y2 - 2024/03/29 TI - A CLINICAL STUDY TO EVALUATE EFFICACY OF TRIVRITADI TAILA ANUVASANA BASTI IN THE MANAGEMENT OF KASHTARTAVA WITH SPECIAL REFERENCE TO PRIMARY DYSMENORRHEA JF - AYUSHDHARA JA - Ayushdhara VL - 6 IS - 5 SE - DO - UR - https://ayushdhara.in/index.php/ayushdhara/article/view/481 SP - 2333-2339 AB - <p>Dysmenorrhea is the most common gynecological problem faced by women during their adolescence and also in reproductive age which causes significant discomfort and anxiety for the women. In modern medicine dysmenorrhea is treated by oral contraceptive pills, non-steroidal anti-inflammatory drugs, antispasmodic, analgesics etc. This treatment may relieve symptoms of dysmenorrhoea but it does not address the root of the problem. Long term use of these causes side effects. So to minimize these complications, an attempt is made to find out safe, potent, cost effective remedy from Ayurveda for the management of <em>Kashtartava. </em>In Ayurveda <em>Kashtartava</em>, term which is being used for the condition where in a women may suffer with pain during menstruation. Pain is the main feature of <em>Kashtartava</em>, so it has strong relation with <em>Vata Dosha</em>. For the management of this vitiated <em>Vata</em>, treatment that effect direct on the place of <em>Vata </em>should be selected therefore by administering <em>Basti </em>to normalize vitiation of <em>Vata</em> and proper measures to correct the <em>Agnivikara </em>should be the prime objectives of the treatment. Keeping this point in view, the present clinical trial, a clinical study to evaluate efficacy of “<em>Trivritadi Taila Anuvasan-Basti</em>” in the management of <em>Kashtartava </em>with special reference to Primary Dysmenorrhea was taken. <em>Trivritadi Taila Anuvasan-Basti </em>due to the properties of <em>Anulomana </em>and <em>Vatahara </em>may it effectively brings down the <em>Pratiloma Gati Vata </em>which is mentioned in <em>A.S.Utt. </em>39/29 for <em>Udavartini Yonivyapad,</em> which is one of the main disease conditions compares with <em>Kashtartava </em>(Primary dysmenorrhoea). Results were assessed on the basis of improvement in the subjective parameters. The study reveals that patients of <em>Kashtartava</em> after treatment showed significant improvement in chief complaints, from the above trial it is clear that <em>Trivritadi Taila Anuvasan-Basti</em> can be used as a safe and effective therapeutic agent in the management of <em>Kashtartava</em>.</p> ER -